ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
Rhea-AI Summary
ALR Technologies (OTC: ALRTF) announced the relaunch of the GluCurve Pet CGM in Canada in January 2026, with a planned U.S. rollout in early Q2 2026 and subsequent global expansion. The company completed internal manufacturing testing showing accuracy comparable to the leading veterinary blood glucose meter and has scheduled an independent non-inferiority study for mid-December. ALR estimates potential annual unit demand of 150,000–300,000 in Canada, 2,000,000–3,000,000 in the U.S., and 2,000,000–3,000,000 in Europe. Manufacturing is partnered with CGM Medical Technology Shenzhen at a Foxconn facility in Shenzhen. Canadian clinics will order from GluCurve.ca at relaunch.
Positive
- Market estimate 150,000–300,000 units/year in Canada
- Market estimate 2,000,000–3,000,000 units/year in U.S.
- Market estimate 2,000,000–3,000,000 units/year in Europe
- Internal testing accuracy comparable to leading veterinary BGM
- Manufacturing partnership with CGM Medical Technology at Foxconn Shenzhen
- Canada relaunch scheduled for January 2026 with U.S. in early Q2 2026
Negative
- Independent non-inferiority study scheduled for mid-December is not yet completed
- U.S. launch depends on an ongoing distributor relationship, not a firm sales date
News Market Reaction – ALRTF
In the Dec 8 session, ALRTF gained 42.86%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Product relaunch plan | Positive | +42.9% | Announced GluCurve relaunch timing and global rollout strategy. |
| Jun 25 | Manufacturing agreement | Positive | +22.2% | Secured definitive CGM manufacturing and exclusive distribution rights. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive GluCurve-related news has coincided with positive price reactions, suggesting sensitivity to commercialization milestones.
Over the last six months, ALR Technologies has focused on advancing its GluCurve Pet CGM commercialization. In June 2025, the company signed a Definitive Manufacturing Agreement with CGM Medical Technology Shen Zhen, securing exclusive global distribution rights and targeting first commercial shipment in Q3 2025, which saw a 22.22% price gain. The current relaunch announcement for January 2026, with U.S. rollout in early Q2 2026 and global expansion, previously coincided with a 42.86% move, underscoring the market’s focus on GluCurve milestones.
Key Terms
continuous glucose monitor medical
blood glucose meter medical
non-inferiority study medical
chemistry analyzer medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GluCurve is the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. A pet-friendly Continuous Glucose Monitor ("CGM") sensor is painlessly attached to the pet and provides blood sugar levels every 3 minutes for up to 14 days. Pet owners can view the blood sugar readings on the GluCurve Pet CGM app. In addition, the blood sugar readings are uploaded to the ALRT Veterinary Web Portal, where they are displayed for the veterinarian to easily manage patients and adjust insulin dosing, either remotely or in person.
Joe Stern, Head of Animal Health at ALRT, states, "Based on the most commonly accepted diabetes prevalence rate studies and pet population surveys, we estimate the potential market size for the GluCurve to be between 150,000-300,000 units per year in
Mr. Stern continued, "We are thrilled to be partnered with CGM Medical Technology Shenzhen Ltd. on the manufacturing of CGM units for GluCurve and the development of a CGM for the human market. We have been working side by side with them to build out their manufacturing capabilities at the Foxconn facility in
ALRT has completed successful internal testing of the GluCurve Pet CGM showing results comparative to the most widely used BGM for cats and dogs, considered the gold standard by veterinarians. An independent non-inferiority study is scheduled for mid-December to further demonstrate its efficacy against the leading veterinary Blood Glucose Meter when compared to a chemistry analyzer.
At relaunch, veterinary clinics in
The Company will announce when GluCurve is for sale in
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and www.GluCurve.com in the
Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 368 3770
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements" as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking statements and information, and the words "anticipate", "estimate", "believe", "continue", "could", "expect", "intend", "plan", "postulates", "predict", "will", "may" or similar expressions suggesting future conditions or events, or the negative of these terms, are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks include all risks and uncertainties expressed in the cautionary statements and risk factors in the annual report on Form 10-K and other filings of ALRT with the SEC. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements include representations to the effect that the Company will launch GluCurve in January 2026, will have sales of GluCurve CGM and will have updates on sales, partnerships, and other material updates related to the distribution of GluCurve. The forward-looking statements included in this news release are made as of the date hereof. ALRT disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/alr-technologies-to-relaunch-the-glucurve-pet-cgm-in-january-2026-302635427.html
SOURCE ALR Technologies SG Ltd.